Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease.

ABSTRACT:

Context

Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients. AGEs proved to be a marker of negative outcome in both diabetes management and surgical procedures in these patients. The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports.

Evidence acquisition

Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles.

Results

Pharmacological approaches in humans include aminoguanidine

SUBMITTER: Nenna A 

PROVIDER: S-EPMC4571620 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature